AIA
GCVRZ

Allegis Investment Advisors’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Allegis Investment Advisors’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-20
Closed – – 1170
2015
Q4 		$0 Buy
+20
New +$3 ﹤0.01% 1164

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Allegis Investment Advisors's GCVRZ Position: Q1 2016 in Review

Allegis Investment Advisors sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2016, closing a stake of 20 shares.

Allegis Investment Advisors first reported a position in GCVRZ in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 106 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2016.

  • Allegis Investment Advisors reported no remaining Sanofi Contingent Value Rights position as of Q1 2016 after selling out during the quarter.
  • Allegis Investment Advisors sold 20 Sanofi Contingent Value Rights shares in Q1 2016.
  • Allegis Investment Advisors first reported a position in Sanofi Contingent Value Rights in Q4 2015 and held it in 1 quarter.
  • Allegis Investment Advisors's Sanofi Contingent Value Rights position peaked at $0 in Q4 2015.
  • 106 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.